Merck KGaA is to begin a Phase IIb trial of its investigational drug sprifermin in patients with osteoarthritis (OA) of …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

